TELMISARTAN 40mg. IP

A long-acting angiotensin II receptor antagonist that is effective in the treatment of hypertension. (Neutel, 2000) Blocks a substance in the body that causes blood vessels to tighten. A preferred option for patients with hypertension. (Domenico Galzerano, 2010) Has superior BP control over different angiotensin-converting enzyme inhibitors (enalapril, ramipril, perindopril). (McFarlane, 2011) Contributes long-term antihypertensive efficacy and is well-tolerated in a broad spectrum of hypertensive patients. (Anna J Battershill, 2006) Offers a significantly greater reduction in diastolic blood pressure compared with enalapril 10 mg. (J H Chen, 2004) Provides superior control of blood pressure in subjects with hypertension in comparison with losartan. (Gui-Lin Xi, 2008) Shows a promising role in diminishing cardiovascular risk in high-risk patients. (Philippe R Akhrass, 2011) A beneficial therapeutic choice in the management of patients with hypertension. (M Sharpe, 2001) A valuable first-line drug for the management of essential hypertension. (Anna J Battershill, 2006) The first choice of treatment in diabetic patients with hypertension. (Pradeep Gadge, 2018) More advantageous than olmesartan for controlling blood pressure in the early morning. (Tatsuya Sasaki, 2008) Lowers both systolic and diastolic blood pressure to a greater extent than valsartan in hypertensive patients. (William B White, 2004)